Literature DB >> 32770721

Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968-2015: A US Population-Based Study.

Eric Y Yen1, Devanshu R Singh2, Ram R Singh3.   

Abstract

OBJECTIVE: To identify secular trends associated with systemic sclerosis (SSc) mortality over a 48-year period.
METHODS: Using national mortality data compiled by the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research, and population data from the US Census Bureau, we calculated an age-standardized mortality rate (ASMR) for SSc and non-SSc (all other causes), and we also calculated the ratio of the SSc ASMR to the non-SSc ASMR for each year from 1968 to 2015. We then used a joinpoint regression model to evaluate mortality trends overall and by sex and race.
RESULTS: From 1968 to 2015, there were 46,798 deaths with SSc recorded as the "underlying" cause of death and 106,058,839 non-SSc deaths. There were an additional 9,063 deaths with SSc recorded as a "contributing" cause of death from 1999 to 2015. Whereas the non-SSc ASMR decreased throughout the 48-year time period, the SSc ASMR increased from 1968 to 2000, followed by decreases each year from 2001 to 2015. The SSc ASMR also decreased for deaths where SSc was a contributing cause from 1999 to 2015. Women and Black persons had higher SSc ASMRs and SSc ASMR to non-SSc ASMR ratios than men and White persons, respectively. Additionally, SSc ASMRs and SSc ASMR to non-SSc ASMR ratios increased at higher rates in women and White persons than in men and Black persons, respectively, during the initial three decades.
CONCLUSION: Mortality attributable to SSc increased from 1968 to 2000, followed by a steady decline from 2001 to 2015. However, SSc mortality relative to non-SSc mortality remains high. SSc mortality has disproportionately changed by sex and race over the 48-year period assessed in the present study.
© 2020, American College of Rheumatology.

Entities:  

Mesh:

Year:  2021        PMID: 32770721      PMCID: PMC7868470          DOI: 10.1002/acr.24411

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  42 in total

Review 1.  Criteria for the classification of early systemic sclerosis.

Authors:  E C LeRoy; T A Medsger
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

2.  Cyclophosphamide versus placebo in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

Review 3.  Mortality and survival in systemic sclerosis: systematic review and meta-analysis.

Authors:  Manuel Rubio-Rivas; Cristina Royo; Carmen Pilar Simeón; Xavier Corbella; Vicent Fonollosa
Journal:  Semin Arthritis Rheum       Date:  2014-05-14       Impact factor: 5.532

4.  Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Authors:  D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

5.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Authors:  R N Channick; G Simonneau; O Sitbon; I M Robbins; A Frost; V F Tapson; D B Badesch; S Roux; M Rainisio; F Bodin; L J Rubin
Journal:  Lancet       Date:  2001-10-06       Impact factor: 79.321

Review 6.  Corticosteroids and the risk of scleroderma renal crisis: a systematic review.

Authors:  Gerald Trang; Russell Steele; Murray Baron; Marie Hudson
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

7.  Racial differences in scleroderma among women in Michigan.

Authors:  T J Laing; B W Gillespie; M B Toth; M D Mayes; R H Gallavan; C J Burns; J R Johanns; B C Cooper; B J Keroack; M C Wasko; J V Lacey; D Schottenfeld
Journal:  Arthritis Rheum       Date:  1997-04

8.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

9.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

Authors:  Maureen D Mayes; James V Lacey; Jennifer Beebe-Dimmer; Brenda W Gillespie; Brenda Cooper; Timothy J Laing; David Schottenfeld
Journal:  Arthritis Rheum       Date:  2003-08

Review 10.  Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment.

Authors:  J Sahhar; G Littlejohn; M Conron
Journal:  Intern Med J       Date:  2004-11       Impact factor: 2.048

View more
  2 in total

1.  Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.

Authors:  Zhaohua Li; Dan Xu; Xintong Jiang; Ting Li; Yin Su; Rong Mu
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

2.  All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019.

Authors:  Vasiliki-Kalliopi Bournia; George E Fragoulis; Panagiota Mitrou; Konstantinos Mathioudakis; Anastasios Tsolakidis; George Konstantonis; Georgia Vourli; Dimitrios Paraskevis; Maria G Tektonidou; Petros P Sfikakis
Journal:  RMD Open       Date:  2021-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.